Peer-reviewedCC BYMedicina (Kaunas, Lithuania)
Cell Viability of the Administered Product Predicts Response to Stromal Vascular Fraction in Patients with Erectile Dysfunction Unresponsive to Phosphodiesterase Type 5 Inhibitors
4 affiliations
- 1Department of Urology, Private Urology Practice, 34158 Istanbul, Türkiye
- 2Private Urology Practice, Oskar Ville Ofisleri, Hürriyet Mahallesi, Necati Sezen Sokak, Kat 1, Süleymanpaşa, 59100 Tekirdağ, Türkiye
- 3Department of Urology, , 34010 Istanbul, Türkiye
- 4Department of Urology, Istanbul Haseki Training and Research Hospital, , 34668 Istanbul, Türkiye
Related
- Efficacy of phosphodiesterase-3 (PDE-3) inhibitors for the treatment of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage (aSAH) admitted to the intensive care unit (ICU): a systematic review and meta-analysis protocol
- Computationally Guided Design of Two Novel Phosphodiesterase-4 Inhibitors for Treatment of Plaque Psoriasis
- Twenty-Hour Hypothermic Oxygenated Perfusion Preserves Myocardial Viability and Bioenergetics with No Primary Graft Dysfunction After Porcine Heart Transplantation
- Targeting cyclic-AMP/phosphodiesterase signaling to quiet nasal tuft cell calcium responses
- Refractory Multivessel Coronary Artery Spasm Unresponsive to Renal Sympathetic Denervation, with Recurrent Transient ST-Segment Elevation and an Episode of Accelerated Idioventricular Rhythm: A Case Report.
BibTeX
@article{guleser2026cell,
title = {{Cell Viability of the Administered Product Predicts Response to Stromal Vascular Fraction in Patients with Erectile Dysfunction Unresponsive to Phosphodiesterase Type 5 Inhibitors}},
author = {Ahmet Semih Güleser and Atakan Eren and Fatih Altunrende and Ufuk Çağlar and Faruk Özgör},
journal = {Medicina (Kaunas, Lithuania)},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13707008},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cell Viability of the Administered Product Predicts Response to Stromal Vascular Fraction in Patients with Erectile Dysfunction Unresponsive to Phosphodiesterase Type 5 Inhibitors
AU - Ahmet Semih Güleser
AU - Atakan Eren
AU - Fatih Altunrende
AU - Ufuk Çağlar
AU - Faruk Özgör
PY - 2026
DA - 2026/10/01
JO - Medicina (Kaunas, Lithuania)
UR - https://europepmc.org/article/PMC/PMC13707008
SN - 1010-660X
SN - 1648-9144
ER -